This could result in serotonin syndrome. This could result in serotonin syndrome. This information is intended for use by health professionalscandidiasis, oral candidiasis, vaginal candidiasis, fungal infectionsantibiotic-associated colitis, including pseudomembranous colitis*leucopenia*, neutropenia, thrombocytopenia*, eosinophiliaheadache, taste perversion (metallic taste), dizzinessoptic neuropathy*, optic neuritis*, loss of vision*, changes in visual acuity*, changes in colour vision*transient ischaemic attacks, phlebitis, thrombophlebitisdiarrhoea, nausea, vomiting, localised or general abdominal pain, constipation, dyspepsiapancreatitis, gastritis, abdominal distention, dry mouth, glossitis, loose stools, stomatitis, tongue discolouration or disorderabnormal liver function test; increased AST, ALT or alkaline phosphatasebullous disorders such as those described as Stevens-Johnson syndrome and toxic epidermal necrolysis, angioedema, alopeciachills, fatigue, injection site pain, increased thirstIncreased LDH, creatine kinase, lipase, amylase or non fasting glucose. Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g. Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents. Decreased haemoglobin, haematocrit or red blood cell count. Consider monitoring lactic acid in patients with renal dysfunction (Mori 2018).Linezolid has been found to have significant interpatient variability (Cattaneo 2016; Pea 2010; Pea 2017) and limited data suggest that monitoring linezolid trough concentrations may be used to optimize dosing, especially in patients with renal dysfunction (Cattaneo 2016; Gervasoni 2015; Pea 2017) and/or concern for thrombocytopenia (Matsumoto 2010; Nukui 2013; Tsuji 2017).Information related to linezolid use during pregnancy is limited (Jaspard 2017; Mercieri 2010). Dapoxetine labeling lists this combination as contraindicated.Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. Alcohol (Ethyl): May enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors.Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk).

As necessary, expert advice should be sought when local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable. Serotonergic Opioids (High Risk): Linezolid may enhance the serotonergic effect of Serotonergic Opioids (High Risk). Unless facilities for close observation and BP monitoring, avoid use in patients w/ uncontrolled HTN, pheochromocytoma, thyrotoxicosis, carcinoid syndrome, bipolar depression, schizoaffective disorder, acute confusional states. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.Opium: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Opium. BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). The duration for non-CNS infection is ≥2 weeks or until clinically stable, whichever is longer. Linezolid oral suspension should be used with caution in those patients with phenylketonuria because the linezolid oral suspension is formulated with aspartame, which supplies roughly 20 mg of phenylalanine per each 5 … Apraclonidine: Monoamine Oxidase Inhibitors may enhance the adverse/toxic effect of Apraclonidine. Tryptophan: Linezolid may enhance the serotonergic effect of Tryptophan.